Combination of Solifenacin and Tamsulosin May Provide Additional Beneficial Effects for Ureteral Stent-related Symptoms-outcomes from a Network Meta-analysis

Overview

Journal World J Urol

Specialty Urology

Date 2018 Jul 22

PMID 30030658

Citations 3

Authors

Zhongyu Jian

Yuntian Chen

Qinyu Liu

Banghua Liao

Tongxin Yang

Hong Li

Kunjie Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: To systematically evaluate the different efficacy among generally used drugs for stent-related symptoms (SRS) with the method of network meta-analysis.

Methods: A systematic search was performed in the US National Library of Medicine's life science database (Medline), Embase, the Cochrane Central Register of Controlled Trials, and the Cochrane Database for Systematic Reviews before December 2017. Analysis was performed under multivariate random-effects network model and effects of drugs were ranked with surface under the cumulative ranking (SUCRA) probabilities.

Results: 19 trials with 2036 patients investigating 4 different intervention including tamsulosin (Tam), alfuzosin (Alfu), solifenacin (Soli) and combination of Tam and Solif were finally included in our analysis. Tam plus Soli had the highest SUCRA on all aspects of ureteral stent symptom questionnaire: urinary symptoms (86.2%), body pain (85.0%), general health (80.5%), work performance (72.0%) and sexual performance (84.4%). Except for pain relief, Soli showed higher SUCRA than Tam or Alfu in rest respects. Tam and Alfu showed similar SUCRA on urinary symptoms (53.0 vs 48.7%) and body pain relief (61.9 vs 62.9%).

Conclusions: Tam plus Soli might be the most effective intervention for SRSs. As for monotherapy, Soli showed advantages in most respects except for pain relief compared to Tam or Alfu. Tam and Alfu showed similar efficacy on urinary symptoms and body pain relief.

Citing Articles

Pharmacological treatment of bladder stent symptoms.

Piedad J, Allam M, Mahmalji W Bladder (San Franc). 2024; 11(3):e21200012.

PMID: 39640188 PMC: 11617032. DOI: 10.14440/bladder.2024.0018.

Comparing efficacy and safety of mirabegron, tamsulosin, and solifenacin in ureteral stent-related symptoms: outcomes from a network meta-analysis.

Xiang N, Hu Y, Peng W, Luo M, Yang Y, Zhang Q Transl Androl Urol. 2024; 13(5):699-707.

PMID: 38855609 PMC: 11157398. DOI: 10.21037/tau-23-642.

Comparison of the efficacy and complications of tolterodine and α-adrenergic receptor blockers in improving ureteral stent-related symptoms: A systematic review and meta-analysis.

Liu M, Liu S, Mao Q, Zou Q, Cui Y, Wu J PLoS One. 2024; 19(5):e0302716.

PMID: 38701097 PMC: 11068181. DOI: 10.1371/journal.pone.0302716.

References

Joshi H, Stainthorpe A, Keeley Jr F, MacDonagh R, Timoney A . Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol. 2001; 15(2):151-4. DOI: 10.1089/089277901750134421. View

Joshi H, Okeke A, Newns N, Keeley Jr F, Timoney A . Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002; 59(4):511-6. DOI: 10.1016/s0090-4295(01)01644-2. View

Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis I . Is there a role for alpha1-blockers in treating double-J stent-related symptoms?. Urology. 2006; 67(1):35-9. DOI: 10.1016/j.urology.2005.07.038. View

Wiebe N, Vandermeer B, Platt R, Klassen T, Moher D, Barrowman N . A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol. 2006; 59(4):342-53. DOI: 10.1016/j.jclinepi.2005.08.017. View

Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo I, DArmiento M . Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol. 2008; 22(4):651-6. DOI: 10.1089/end.2007.0257. View

Beddingfield R, Pedro R, Hinck B, Kreidberg C, Feia K, Monga M . Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol. 2008; 181(1):170-6. DOI: 10.1016/j.juro.2008.09.026. View

Wang C, Huang S, Chang C . Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res. 2009; 37(3):147-52. DOI: 10.1007/s00240-009-0182-8. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

Park S, Jung S, Lee J, Rim J . The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol. 2009; 23(11):1913-7. DOI: 10.1089/end.2009.0173. View

10.

Salanti G, Ades A, Ioannidis J . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010; 64(2):163-71. DOI: 10.1016/j.jclinepi.2010.03.016. View

11.

Mokhtari G, Shakiba M, Ghodsi S, Farzan A, Nejad S, Esmaeili S . Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial. Urol Int. 2011; 87(1):19-22. DOI: 10.1159/000323855. View

12.

Kuyumcuoglu U, Eryildirim B, Tuncer M, Faydaci G, Tarhan F, Ozgul A . Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J. 2011; 6(6):E234-7. PMC: 3529727. DOI: 10.5489/cuaj.10143. View

13.

Nazim S, Ather M . Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial. J Endourol. 2012; 26(9):1237-41. DOI: 10.1089/end.2012.0036. View

14.

Yamaguchi O . Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol. 2012; 20(1):28-39. DOI: 10.1111/iju.12008. View

15.

Lee Y, Huang K, Yang H, Chang H, Chen J, Yang T . Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013; 41(3):247-52. DOI: 10.1007/s00240-013-0554-y. View

16.

Mills E, Thorlund K, Ioannidis J . Demystifying trial networks and network meta-analysis. BMJ. 2013; 346:f2914. DOI: 10.1136/bmj.f2914. View

17.

Dellis A, Keeley Jr F, Manolas V, Skolarikos A . Role of α-blockers in the treatment of stent-related symptoms: a prospective randomized control study. Urology. 2013; 83(1):56-61. DOI: 10.1016/j.urology.2013.08.067. View

18.

Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M . Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol. 2014; 39(6):832-40. DOI: 10.1590/S1677-5538.IBJU.2013.06.09. View

19.

Singh I, Tripathy S, Agrawal V . Efficacy of tamsulosin hydrochloride in relieving "double-J ureteral stent-related morbidity": a randomized placebo controlled clinical study. Int Urol Nephrol. 2014; 46(12):2279-83. DOI: 10.1007/s11255-014-0825-8. View

20.

Lange D, Bidnur S, Hoag N, Chew B . Ureteral stent-associated complications--where we are and where we are going. Nat Rev Urol. 2014; 12(1):17-25. DOI: 10.1038/nrurol.2014.340. View